Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
The purpose of this study was to determine the effects of bisphosphonates periprosthetic BMD in THA patients as a function of stem design. Specifically, the goals were to determine if bisphosphonates as a group could significantly inhibit periprosthetic bone loss, time needed to see an effect, if one drug was more effective than the others, and if there was a difference due to stem design or cement. Thirteen articles met the inclusion criteria. Overall, groups treated with bisphosphonate therapy preserved significantly more BMD than the control groups as early as six months postoperatively, and orally delivered bisphosphonates were most effective. Furthermore, the biggest differences were in patients with non-cemented stems, and of those, the largest differences were seen in patients with fully coated CoCr stems.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.arth.2014.01.015 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!